Recently, Gilead Sciences held the closing ceremony of the 10th anniversary of the global listing of Sofobuvir and the 5th anniversary of the listing of Velix and Epclusa in China in Guangzhou. Fangmin Xie, founder, chairman and CEO of Ark Jianke, was invited to attend the event and had a meeting with experts, scholars and industry partners in the field of liver disease.
The prevention and treatment of viral hepatitis in China is still facing the challenges of "low diagnosis rate" and "low rate". However, the goal of eliminating viral hepatitis has entered the countdown, and the task of prevention and control is arduous. Gilead Sciences is always exploring.
At Gilead, we are committed to pushing the boundaries of the impossible and continuing to drive drug innovation to address life-threatening diseases. This year marks the 10th anniversary of the global launch of sofosbuvir and the 5th anniversary of the launch of Vedex and Epclusa in China, and I am delighted that our innovation** has helped many patients in China.
At the event, Jin Fangqian, Vice President and General Manager of Gilead Sciences China, said in his speech that in addition to promoting scientific research and development and introducing innovative drugs, Gilead has always adhered to the patient-centered approach and continued to actively cooperate with all levels of society, health institutions, industry associations and other social parties, so as to better serve Chinese patients and contribute wisdom and strength to the elimination of viral hepatitis in China.
With the continuous innovation of antiviral drugs for hepatitis B and C, coupled with the significant reduction in the cost of national medical insurance negotiations and centralized volume procurement, the goal path to eliminate viral hepatitis is becoming clearer. At the symposium on "Working Together to Create a Future Without Hepatitis", several professors working in the front line shared their experience of hepatitis**, and they jointly said that there is no need to "talk about liver discoloration", and when infected people are found, they should be allowed to take the initiative to accept ** from multiple levels to achieve "all treatments".
Eliminating hepatitis B is not only a medical problem that needs to be overcome, but also requires all sectors of society to work together to eliminate social discrimination. In the session of "Multi-party Cooperation to Escort the Elimination of Hepatitis", Xie Fangmin, Founder, Chairman and CEO of Ark Jianke, Yu Jiehao, Deputy General Manager of China Resources Guangdong Pharmaceutical, and Wu Yu, Head of Hepatitis Business Unit of Gilead Sciences, shared their respective views.
There are more than 80 million chronic hepatitis B virus carriers in China, so that they can get better diagnosis and treatment services and use better quality medicines, which is the original intention of Ark Healthcare's mission to "make everyone healthier", and it is also the goal that Gilead hopes to achieve. From 0 to 1, in the past five years, Ark Health has joined hands with Gilead to build a "Liver Disease Prevention and Treatment Zone" on the platform, and attracted many doctors in the field of infectious liver diseases to settle in, jointly providing professional chronic disease management services for hepatitis patients across the country, including ** consultation, follow-up prescription renewal, health management, science popularization and education, etc., which have been widely acclaimed.
After 5 years of cooperation, we have always believed that Gilead is a trustworthy, respectful and win-win partner. Recalling the cooperation process, Xie Fangmin was most impressed by the first online prescription between Ark Health and Gilead South in 2018. He said: "This prescription is a good starting point, and in the future, we will continue to promote the expansion of antiviral** in the guidelines for the prevention and treatment of chronic hepatitis B, focusing on disease awareness education for patients who should not be treated, and guiding patients to start early**." "Our Internet Hospital team is a perfect match for Gilead's regional footprint, and we look forward to continuing to strengthen our close partnership to better serve patients and benefit the people." ”
There is still a long way to go to achieve the goal of hepatitis elimination, and more efforts need to be mobilized. At the event, the guests expressed their blessings to Gilead Scientific's 10th anniversary of the global launch of sofobuvir and the 5th anniversary of the launch of Vedide and Epclusa in China, and expressed their willingness to continue to work together to build a strong line of defense for the health of more than 80 million chronic hepatitis B virus carriers in China.
On the road to the elimination of hepatitis, Ark Health will also give full play to the advantages of its own Internet + chronic disease services, move forward side by side with more partners, help more patients improve their health, and contribute the wisdom and strength of the enterprise to the goal of eliminating hepatitis.